よむ、つかう、まなぶ。
資料4-3 リツキシマブ（遺伝子組換え） (21 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00032.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第58回 3／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-87
ontractOption=all&sortBy=relevance&bc=1（最終確認日 2024 年 2 月 14 日）
20) Local Coverage Determination (LCD): Off-label Use of Rituximab and Rituximab Biosimilars
(L35026). Medicare Coverage Database. Available from: https://www.cms.gov/medicarecoverage-database/view/lcd.aspx?LCDId=35026（最終確認日2024年2月14日）
21) Local Coverage Determination (LCD): Immune Thrombocytopenia (ITP) Therapy (L38268).
Medicare Coverage Database. Available from: https://www.cms.gov/medicare-coveragedatabase/view/lcd.aspx?lcdid=38268&ver=8&bc=0（最終確認日2024年2月14日）
22) Matzdorff A, et al. Expert Report on Immune Thrombocytopenia:Current Diagnostics and
Treatment –Recommendations from an Expert Group from Austria, Germany, and Switzerland.
Oncol Res Treat 2023: 46; 5-44.
23) Wang J, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab
treatment. J Pediatr. 2005; 146: 217-21.
24) Gokcebay DG, et al. Evaluation of children with chronic immune thrombocytopenic purpura and
Evans syndrome treated with rituximab. Clin Appl Thromb Hemost. 2013; 19: 663-7.
25) Dogan M, et al. Treatment of chronic immune thrombocytopenic purpura with rituximab. Indian
J Pediatr. 2009; 76: 1141-4.
26) Matsubara K, et al. Long-term follow-up of children with refractory immune thrombocytopenia
treated with rituximab. Int J Hematol. 2014; 99: 429-36.
27) Del Vecchio GC, et al. Chronic immune thrombocytopenia in childhood. Blood Coagul
Fibrinolysis. 2014; 25: 297-9.
28) Tarantino MD, et al. Update on the management of immune thrombocytopenic purpura in
children. Curr Opin Hematol. 2007; 14: 526-34.
29) Taube T, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura
in childhood. Haematologica. 2005; 90: 281-3.
30) Parodi E, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory
symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol.
2006; 84: 48-53.
31) Singh G, et al. Immune Thrombocytopenia in Children: Consensus and Controversies. Indian
Journal of Pediatrics. 2020; 87: 150-7.
32) Goldman-Cecil Medicine. 25th Edition. Elsevier Health Science; 2015. p1163-4.
33) WINTROBE's CLINICAL HEMATOLOGY 14th EDITION. Wolters Kluwer; 2018. p1399400.
34) Harrisonn’s Principles of Internal Medicine 21st Edition. McGraw-Hill Education; 2022. p9067.
35) 血液専門医テキスト 改訂第 4 版. 日本血液学会（編）.南江堂; 2023. p410-3.
36) 石黒精、他. 日本小児血液・がん学会 2022 年小児免疫性血小板減少症診療ガイドライ
ン. 日本小児血液・がん学会雑誌 2022; 59: 50-7.
21
92 / 213
ontractOption=all&sortBy=relevance&bc=1（最終確認日 2024 年 2 月 14 日）
20) Local Coverage Determination (LCD): Off-label Use of Rituximab and Rituximab Biosimilars
(L35026). Medicare Coverage Database. Available from: https://www.cms.gov/medicarecoverage-database/view/lcd.aspx?LCDId=35026（最終確認日2024年2月14日）
21) Local Coverage Determination (LCD): Immune Thrombocytopenia (ITP) Therapy (L38268).
Medicare Coverage Database. Available from: https://www.cms.gov/medicare-coveragedatabase/view/lcd.aspx?lcdid=38268&ver=8&bc=0（最終確認日2024年2月14日）
22) Matzdorff A, et al. Expert Report on Immune Thrombocytopenia:Current Diagnostics and
Treatment –Recommendations from an Expert Group from Austria, Germany, and Switzerland.
Oncol Res Treat 2023: 46; 5-44.
23) Wang J, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab
treatment. J Pediatr. 2005; 146: 217-21.
24) Gokcebay DG, et al. Evaluation of children with chronic immune thrombocytopenic purpura and
Evans syndrome treated with rituximab. Clin Appl Thromb Hemost. 2013; 19: 663-7.
25) Dogan M, et al. Treatment of chronic immune thrombocytopenic purpura with rituximab. Indian
J Pediatr. 2009; 76: 1141-4.
26) Matsubara K, et al. Long-term follow-up of children with refractory immune thrombocytopenia
treated with rituximab. Int J Hematol. 2014; 99: 429-36.
27) Del Vecchio GC, et al. Chronic immune thrombocytopenia in childhood. Blood Coagul
Fibrinolysis. 2014; 25: 297-9.
28) Tarantino MD, et al. Update on the management of immune thrombocytopenic purpura in
children. Curr Opin Hematol. 2007; 14: 526-34.
29) Taube T, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura
in childhood. Haematologica. 2005; 90: 281-3.
30) Parodi E, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory
symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol.
2006; 84: 48-53.
31) Singh G, et al. Immune Thrombocytopenia in Children: Consensus and Controversies. Indian
Journal of Pediatrics. 2020; 87: 150-7.
32) Goldman-Cecil Medicine. 25th Edition. Elsevier Health Science; 2015. p1163-4.
33) WINTROBE's CLINICAL HEMATOLOGY 14th EDITION. Wolters Kluwer; 2018. p1399400.
34) Harrisonn’s Principles of Internal Medicine 21st Edition. McGraw-Hill Education; 2022. p9067.
35) 血液専門医テキスト 改訂第 4 版. 日本血液学会（編）.南江堂; 2023. p410-3.
36) 石黒精、他. 日本小児血液・がん学会 2022 年小児免疫性血小板減少症診療ガイドライ
ン. 日本小児血液・がん学会雑誌 2022; 59: 50-7.
21
92 / 213